Werewolf Therapeutics Inc (NASDAQ: HOWL) on Tuesday, soared 1.79% from the previous trading day, before settling in for the closing price of $1.12. Within the past 52 weeks, HOWL’s price has moved between $0.60 and $5.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -13.79% annually for the last half of the decade. The company achieved an average annual earnings per share of -9.00%. With a float of $33.12 million, this company’s outstanding shares have now reached $44.83 million.
In an organization with 46 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 60.28%, operating margin of -4937.18%, and the pretax margin is -6335.17%.
Werewolf Therapeutics Inc (HOWL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Werewolf Therapeutics Inc is 26.20%, while institutional ownership is 47.51%. The most recent insider transaction that took place on May 12 ’25, was worth 275,985. In this transaction Director of this company bought 320,913 shares at a rate of $0.86, taking the stock ownership to the 6,021,969 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 162,539 for $0.98, making the entire transaction worth $159,288. This insider now owns 6,237,482 shares in total.
Werewolf Therapeutics Inc (HOWL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -9.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.48% during the next five years compared to -20.76% drop over the previous five years of trading.
Werewolf Therapeutics Inc (NASDAQ: HOWL) Trading Performance Indicators
Werewolf Therapeutics Inc (HOWL) is currently performing well based on its current performance indicators. A quick ratio of 8.09 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 44.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.64, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -1.62 in one year’s time.
Technical Analysis of Werewolf Therapeutics Inc (HOWL)
Let’s dig in a bit further. During the last 5-days, its volume was 1.26 million. That was better than the volume of 0.32 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 74.34%. Additionally, its Average True Range was 0.10.
During the past 100 days, Werewolf Therapeutics Inc’s (HOWL) raw stochastic average was set at 48.44%, which indicates a significant decrease from 78.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.87% in the past 14 days, which was higher than the 90.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9512, while its 200-day Moving Average is $1.6338. However, in the short run, Werewolf Therapeutics Inc’s stock first resistance to watch stands at $1.2133. Second resistance stands at $1.2867. The third major resistance level sits at $1.3433. If the price goes on to break the first support level at $1.0833, it is likely to go to the next support level at $1.0267. Assuming the price breaks the second support level, the third support level stands at $0.9533.
Werewolf Therapeutics Inc (NASDAQ: HOWL) Key Stats
Market capitalization of the company is 51.16 million based on 44,874K outstanding shares. Right now, sales total 1,890 K and income totals -70,520 K. The company made 0 K in profit during its latest quarter, and -18,090 K in sales during its previous quarter.
